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Abstract
The incidence of gastric cancer (GC) is decreasing 
worldwide, especially for intestinal histotype of the 
distal third of the stomach. On the contrary, proximal 
location and diffuse Lauren histotype have been 
reported to be generally stable over time. In the 
west, no clear improvement in long-term results was 
observed in clinical and population-based studies. 
Results of treatment in these neoplasms are strictly 
dependent on tumor stage. Adequate surgery and 
extended lymphadenectomy are associated with good 
long-term outcome in early-stage cancer; however, 
results are still unsatisfactory for advanced stages (Ⅲ 
and Ⅳ), for which additional treatments could provide 
a survival benefit. This implies a tailored approach to 
GC. The aim of this review was to summarize the main 
multimodal treatment options in advanced resectable 
GC. Perioperative or postoperative treatments, including 
chemotherapy, chemoradiotherapy, targeted therapies, 
and hyperthermic intraperitoneal chemotherapy have 
been reviewed, and the main ongoing and completed 
trials have been analyzed. An original tailored multi-
modal approach to non-cardia GC has been also 
proposed. 
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Core tip: In advanced gastric cancer (GC), multimodal 
treatment is currently an option in the west. Adequate 
surgery and extended lymphadenectomy, together with 
survival worsened over time for patients with non-
cardiac tumors, whereas the risk of death decreased 
for patients with cardiac tumors[12].
Different epidemiological trends in the intestinal 
type (IT) and diffuse type (DT) Lauren histotypes have 
also been observed. The declining incidence of GC 
has been linked to the decreasing number of ITs; on 
the contrary, the incidence of DT is generally stable 
throughout the world[10,13-15]. As most proximal tumors 
are IT, it is important, when evaluating epidemiological 
trends, to group data according to histotype and 
location. In a recent study from the Italian Research 
Group for Gastric Cancer (GIRCG), a decreasing number 
of IT tumors of the distal stomach was observed; on 
the contrary, IT located in the proximal third, and DT, 
at any location, were stable over time[9]. As a conse-
quence, the DT neoplasms showed a relative increase 
with time (Figure 1). 
Recent studies have also reported different trends 
of GC incidence in young patients; declining rates were 
observed for subjects aged 40-84 years, whereas for 
younger cohorts, the incidence rates increased over 
time[16]. Recent reports from Europe also confirm 
these findings[17]. The higher prevalence of DT in 
young patients may explain the epidemiological trends 
described for specific histotypes of GC.
As for GC prevention, two potential strategies 
are proposed. Primary prevention is possible due to 
eradication of H. pylori, and secondary prevention 
by detection of GC in mass screening[4]. Primary 
prevention is based on the fact that H. pylori is the 
strongest known factor associated with distal IT GC. It 
is possible to eradicate the infection using antibiotics 
in association with an antisecretory agent. It is 
proposed to offer prophylactic eradication for high-risk 
individuals, or for patients in high-risk areas.
For secondary prevention, mass screening is 
performed in countries with the highest incidence 
of GC. In Japan or South Korea the screening pro-
grams seem to be effective, with the higher rate of 
early GC detection, improved 5-year survival, and 
improved proportion of localized GC at diagnosis[4,17]. 
The main screening methods are barium X-ray, 
combination of barium digital radiography together 
with serum pepsinogen testing, and endoscopy with 
photofluorography. However, mass screening is hard 
to promote and organize in low-risk areas, where few 
but more advanced GC cases, mainly with proximal 
location or DT tumors, are generally observed in clinical 
practice[4].
CLINICAL IMPLICATIONS OF CHANGING 
EPIDEMIOLOGY
The above-mentioned epidemiological trends could 
have important clinical implications. Indeed, the overall 
number of newly diagnosed GC cases is decreasing, 
but the relative percentage of proximal locations and 
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modern chemotherapy, radiotherapy, targeted therapies, 
and a combination of all could possibly improve survival 
in advanced GC. A tailored multimodal approach is 
strictly necessary in the light of treatment results and 
recent epidemiological trends, which indicate a relative 
increase of more aggressive forms, such as proximal 
location and diffuse Lauren histotype in the west. The 
main ongoing and completed clinical trials regarding 
multimodal approach to GC have been reviewed, and 
an original tailored multimodal protocol to non-cardia 
GC has been proposed.
Marrelli D, Polom K, de Manzoni G, Morgagni P, Baiocchi GL, 
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are we going? World J Gastroenterol 2015; 21(26): 7954-7969 
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CHANGING EPIDEMIOLOGY OF GASTRIC 
CANCER
Despite the reported declining incidence, gastric cancer 
(GC) is one of the most common causes of cancer 
mortality worldwide[1-3]. It represents the fourth most 
common cancer after lung, breast and colorectal 
cancer, and the second most common cause of cancer-
related death after lung cancer. Geographic variability 
of GC is also well known: highest incidence rates are 
observed in East Asia, Central Asia, Eastern Europe, 
and the Pacific Coast of South and Central America, 
whereas the lowest incidence rates are found in 
Northern Europe and North America[4]. Even within the 
same country, there can be wide variation in geographic 
incidence: for example, in Italy, mortality is high in the 
central region, especially along the Central Apennine 
Mountains, and very low in Southern Italy[5,6]. Even 
if partly obscured by population aging, a decreasing 
incidence of GC has been reported worldwide in 
recent decades. This epidemiological trend has been 
attributed to several factors, such as the increased 
consumption of vegetables and fruit instead of cured 
meat, and changed methods of food conservation 
(refrigeration, instead of salt preservation)[7]. The 
decreased prevalence of Helicobacter pylori (H. pylori) 
infection has also had a role. However, decreasing rates 
are more evident in high-risk areas, whereas in low-
risk areas, the rates have fallen slowly, with a trend to 
become stable over time[5,6,8,9].
Certain subtypes of GC demonstrate different 
epidemiological features. Tumors located in the distal 
third of the stomach have shown the most evident 
decrease in incidence, whereas proximal tumors are 
stable or even increasing[10,11]. This trend has been 
confirmed in some recent studies: the incidence 
decreased among men and women, but the proportion 
of cardiac tumors remained stable over time; 5-year 
DT is increasing. Proximal tumors, including those 
involving the esophagogastric junction (EGJ), are 
associated with higher clinical aggressiveness and 
worse prognosis[9,18-21]. The relative increase in the 
proportion of proximal tumors could lead to a general 
decrease in survival probability.
Another important consequence of epidemiological 
trends is the relative increase in DT tumors (Figure 
2). Besides histomorphometrical characteristics, IT 
and DT histotypes show evident differences in epide-
miological, clinical and molecular features[22]. IT type 
is more common in males and older patients, whereas 
DT type usually affects younger patients with a lower 
male-female ratio. Environmental factors seem to 
be involved in the pathogenesis of IT tumors, and 
they usually follow the sequence of chronic atrophic 
gastritis, intestinal metaplasia, and dysplasia. On the 
contrary, DT tumors usually originate from healthy 
gastric mucosa or non-atrophic gastritis, and are more 
related to genetic factors. A further characteristic of 
the DT is their greater biological aggressiveness. The 
risk of lymph node metastasis is higher in the DT 
than the IT, at the same T stage. Indeed, the DT is a 
strong risk factor for lymph node metastasis in early 
GC[23], but an increased risk is also present in more 
advanced pT stages. The correlation between lymph 
node metastasis and Lauren histotype, stratified for 
pT stage, has been evaluated in 2090 non-cardia GC 
patients from the GIRCG database (Figure 3). The 
incidence and number of lymph node metastases were 
notably higher in the DT than IT groups at the same pT 
stage. Furthermore, DT is also a risk factor for lymph 
node metastases in extra-regional nodal locations (such 
as para-aortic nodes)[24,25].
The higher probability of lymph node metastases in 
DT could be an indication for more extended lympha-
denectomy or neoadjuvant treatment. In contrast, 
clinical diagnosis, by radiological imaging, of lymph 
node metastasis may be more difficult in the DT. It 
has been reported that, in this histotype, the size of 
involved nodes may be smaller than the commonly 
used cut-off values[22]. 
Besides the lymph node involvement, DT tumors 
also show a greater propensity to peritoneal spread. 
Indeed, several studies have demonstrated a higher 
risk of peritoneal recurrence in DT tumors; mainly 
when the tumor has serosal involvement[22,26]. 
In a GIRCG follow-up study, the 5-year risk of 
peritoneal recurrence has been calculated to be 69% 
in DT GC with serosal involvement, vs 20% for IT 
cases at the same pT stage. It has been demonstrated 
that the clinical impact of extended surgery, including 
D2/D3 lymphadenectomy, is of low value in serosally 
exposed forms at risk of peritoneal recurrence[27,28].
The chance of cure in patients with peritoneal 
recurrence of GC is low: in a GIRCG follow-up study, 
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Figure 1  Changing number of patients in three subperiods, stratified according to tumor location and Lauren histotype (GIRCG database).
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Figure 2  Images of intestinal (A, C) and diffuse type (B, D) tumors of the stomach. The arrow in D indicates the infiltrative growth of the diffuse histotype in the 
gastric wall.
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Figure 3  Incidence of lymph node metastases according to Lauren histotype stratified for pT stages (GIRCG database).
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5-year survival probability in 221 patients with metachro-
nous peritoneal carcinomatosis (PC) was only 3% (Figure 
4)[29]. As such, prevention of peritoneal recurrence, 
more than treatment after its occurrence, may be the 
only potential chance of cure in high-risk cases[30]. 
Late-phase DT GC can evolve into diffuse infiltra-
tion, thickening and stiffening of the gastric wall with 
reactive fibrosis, also named gastric linitis plastica. 
This is a subset of GC with a large propensity to 
diffuse infiltration, massive lymph node metastasis, 
and peritoneal seeding[31]. The rate of radical resection 
in this form of GC is < 30%, and, even after R0 
resection, the 5-year survival probability does not 
exceed 5%. Some population-based studies from 
Europe, along with the decreased incidence of GC, 
have reported a significant increase of gastric linitis 
plastica with time[32]. These data are consistent with 
previously mentioned epidemiological trends.
Pathological characteristics of different histotypes 
of GC may explain epidemiological and survival data 
reported in large European studies. Recent data 
from 49 cancer registries in 18 European countries 
(EUROCARE-4 Working Group) have revealed a 
notable survival increase in Europe over the period 
1988-1999 for several cancer sites, in particular, for 
prostate, colorectal and breast cancer. However, for 
GC, the increase was small (from 22% to 24%), 
despite potential time-related improvements in 
diagnosis, surgical and medical treatment[33]. Survival 
improvement was higher for men (4.1%) than women 
(1.4%). The declining incidence of cancers of the distal 
stomach could help to explain these survival trends. 
Indeed tumors of the cardia or fundus are usually 
diagnosed in older patients, at an advanced stage, 
and with diffuse/signet ring cell morphology. Other 
population-based and clinical studies reported similar 
results. In the previously mentioned French study, the 
global prognosis of GC did not improve significantly 
over a 12-year period of observation[32]. Recent 
studies from the Netherlands have also confirmed the 
decreasing incidence of GC but stable survival rates 
over time[34]. 
These data seem to be consistent with the findings 
of a previous GIRCG study: along with the decreasing 
number of distal IT tumors and the relative increase of 
DT forms with time, a lack of improvement of cancer-
related survival probability, and a significant increase 
of peritoneal recurrence after surgery were observed[9]. 
In particular, survival rates decreased in the more 
recent period in the group of patients with serosal 
involvement, in women, and in distal tumors, whereas 
an increasing trend was observed in proximal tumors. 
All these data may fit with the hypothesis that the 
relative increase in DT tumors may have contributed to 
the absence or small improvement of treatment of GC 
in western countries.
TREATMENT OF EARLY FORMS
Surgical treatment with adequate lymphadenectomy 
could offer a high probability of cure even in western 
patients. Survival rates in early stages reported 
from specialized western centers are similar to those 
obtained in Japan and South Korea[21,27,35]. 
Selected forms of early GC can be treated by 
endoscopic mucosal resection or endoscopic submu-
cosal dissection, in accordance with the standard 
criteria described by the Japanese Gastric Cancer 
Association (JGCA), with acceptable results even in the 
west[36,37]. The resection is judged as curative when 
all of the following conditions are fulfilled: en bloc 
resection, tumor size not greater than 2 cm, histology 
of intestinal-differentiated-type, pT1a, negative 
horizontal (lateral) margin, negative vertical margin, 
and no lymphovascular invasion.
Although endoscopic approaches to early forms of 
GC are increasing in specialized centers in the west, 
they are still far from becoming a clinical standard. 
Early forms not treatable by endoscopic resection 
should be submitted to surgical resection with 
lymphadenectomy. According to the JGCA treatment 
guidelines[36], D1 lymphadenectomy may be adequate 
for early GC with clinically negative lymph nodes. 
However, we should underline that a proportion of 
early GC in the west is DT, which is associated with 
a higher risk of lymph node metastases and greater 
lymph node spread, especially when submucosa 
is involved. Furthermore, in the west, endoscopic 
resection, which can be considered as a treatment 
as well as a staging procedure, is performed less 
frequently than in East Asia, and the clinical diagnosis 
of lymph node metastasis by imaging procedures still 
has low accuracy[38]. As such, the Italian guidelines 
advise standard D2 lymphadenectomy in early forms 
of GC[39]. Only in selected cases (high-risk patients, 
early forms with favorable pathological characteristics, 
not treatable by endoscopic resection) should more 
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Figure 4  Survival rate of patients with peritoneal recurrence of gastric 
cancer.
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limited procedures be considered (D1 plus).
Early forms of GC could also be treated by mini-
mally invasive (laparoscopic or robotic) approaches, 
which demonstrated non-inferior oncological results 
compared with open surgery[40,41]. However, it should 
be emphasized that oncological criteria regarding 
resection margin and lymph node dissection need to 
be carefully followed in minimally invasive procedures.
TREATMENT OF ADVANCED 
RESECTABLE FORMS
In advanced resectable forms of GC, it is now well 
established that adequate surgical treatment is a 
key factor in obtaining acceptable long-term results. 
As for the extent of resection, subtotal gastrectomy 
offers low postoperative morbidity and mortality 
risk, and better quality of life, without affecting long-
term oncological results, when an adequate resection 
margin can be obtained (R0 resection)[42]. A proximal 
margin of at least 3 cm is recommended for T2 or 
deeper tumors with an expansive growth pattern, 
and 5 cm is recommended for DT and tumors with 
infiltrative growth pattern. In all other cases, total 
gastrectomy should be the preferred procedure. 
In early GC, a resection margin of 2 cm may be 
enough[39]. Total gastrectomy with splenectomy should 
be also recommended for tumors located along the 
greater curvature. Splenectomy should be performed 
only when macroscopic involvement of lymph nodes at 
the splenic hilum is present. 
The extent of lymphadenectomy is crucial. Even if 
some randomized studies have failed to demonstrated 
a significant advantage for overall survival, a re-
evaluation of the Dutch trial showed a reduced cancer-
related survival in the long term and a higher incidence 
of late recurrence of GC in patients submitted to 
limited (D1) lymphadenectomy[43]. 
It is important to ensure that good early post-
operative results in terms of morbidity and mortality 
are achieved. This is consistent with the reports of 
observational nonrandomized studies from specialized 
centers[44,45].
Nowadays, D2 lymphadenectomy is generally 
accepted as the standard approach in most national 
guidelines[39,46]. The correct procedure for lympha-
denectomy involves the removal of nodal stations from 
1 to 12, with some variations depending upon the 
extent of gastric resection[36]. Special attention should 
be paid upon to the complete removal of infrapyloric 
nodes (station 6), right paracardial nodes (station 1), 
left gastric artery nodes (station 7), celiac axis (station 
9), hepatic artery (station 8a), splenic artery (station 
11), and hepatoduodenal ligament nodes (station 
12a). 
More extended lymphadenectomies (D2+) can be 
performed in selected cases at risk of metastasis to 
posterior (stations 8p, 12p, 12b and 13), mesenteric 
(station 14) or para-aortic (stations 16a2 and b1) 
lymph nodes, in specialized centers and in the setting 
of clinical studies[22,23]. In particular, proximal or DT 
tumors are particularly prone to metastasis to distant 
nodes, and in our opinion they may benefit from 
super-extended lymphadenectomy[25,28]. However, it 
should be emphasized that in more advanced stages 
(UICC TNM stages ⅢA and more) the results of 
surgery, even with adequate lymphadenectomy, are 
still unsatisfactory in western patients[35]. As such, 
additional treatments should be planned to improve 
long-term survival in these patients.
MULTIMODAL TREATMENT OF GASTRIC 
CANCER
Neoadjuvant treatment seems to be a good option 
in advanced GC. The term advanced should be 
understood as a T3, T4 and/or N+ and/or with positive 
peritoneal cytology. The majority of patients who are 
diagnosed at this stage might receive benefits from 
perioperative treatment. 
Even though dietary changes and the use of 
antibiotics to treat chronic H. pylori infection have 
helped to reduce steadily the number of new cases 
of GC, the progress in GC treatment is still limited[47]. 
Surgery remains the only treatment with curative 
intent in locoregional disease. From an oncological 
point of view the issue is to resect the cancer with a 
negative resection margin (R0), and with adequate 
lymph node dissection. The biggest problem, especially 
in the west, is diagnosis of patients with locally 
advanced disease. Advanced disease is associated with 
a higher rate of locoregional recurrence. For locally 
advanced forms, additional multimodal treatment 
in the preoperative, perioperative and postoperative 
phases has been proposed. Nowadays, we can observe 
geographic differences in multimodal treatment of 
GC. In Asia, the most commonly used treatment is 
adjuvant chemotherapy; in the United States, the 
favored treatment is chemoradiotherapy (CRT); and in 
Europe, neoadjuvant therapy is mostly used. 
Advanced GC still has a poor survival (< 30% 5-year 
survival probability for stage Ⅲ). Cunningham et al[48] 
and Ychou et al[49] have demonstrated the advantage 
of starting multimodal treatment with preoperative 
chemotherapy over surgery alone, therefore, this 
seems to be a good treatment option. In the trial by 
Schuhmacher et al[50], neoadjuvant therapy improved 
R0 resection rate even though it did not improve 
overall survival (OS). In the study by Stahl et al[51], 
neoadjuvant CRT showed a higher rate of complete 
responders, and in the study by van Hagen et al[52], 
improved OS was observed. 
In Asian countries in contrast, the greatest interest 
lies in postoperative oral chemotherapy, which is 
associated with improved OS compared with surgery 
alone[53,54]. However, these results have not been 
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reproduced in western countries. 
In the United States, CRT has been used routinely 
since 2001, after the trial of MacDonald et al[55]. 
Neoadjuvant chemotherapy
The neoadjuvant approach is currently recommended 
across Europe based on the Magic and FNLCC/FFCD 
trial[48,49]. Other benefits of neoadjuvant chemotherapy 
(NC), discussed by Ott et al[56], for potentially 
resectable GC are higher rate of R0 resection achieved 
by downstaging of a primary tumor, and probable 
effect on micrometastases and isolated tumor cells 
in lymph nodes. Ott et al emphasized also that the 
neoadjuvant setting is more often proposed for 
younger patients and those in general good health. 
In the Magic trial, chemotherapy consisted of 
three cycles of intravenous (i.v.) epirubicin, cisplatin 
and 5-fluorouracil (FU) preoperatively and three 
cycles postoperatively[48]. NC was not associated with 
worse postoperative complications and 30-d mortality 
than surgery alone, thus overturning the argument 
that neoadjuvant therapy may be more dangerous 
for patients. From the main results, 5-year survival 
rate was 36% vs 23% in favor of perioperative 
chemotherapy. Also, OS and progression-free survival 
(PFS) were significantly better. Only 49.5% of 
patients received the full perioperative chemotherapy 
treatment, therefore, this was one of the main issues 
criticized by some investigators. This issue was 
investigated in the study by Mirza et al[57] in which it 
was checked in patients using the same regimen as 
in the Magic trial. The full perioperative regimen had 
a beneficial effect on DFS but not on OS. It may be 
concluded that administrating the adjuvant part of 
this regimen postponed tumor recurrence rather than 
helping in prevention.
The FNLCC/FFCD trial proved the beneficial effect of 
perioperative chemotherapy for gastric and esophageal 
adenocarcinoma[49]. In the preoperative period, 
two or three cycles of i.v. cisplatin and 5-FU were 
administered, and after surgery, chemotherapy was 
continued when response to treatment was observed. 
A higher rate of R0 resection in NC in comparison with 
surgery alone was observed, as well as improved OS 
and DFS. The 5-year survival rates were 38% vs 24% 
in favor of NC. 
In a meta-analysis by Ronellenfitsch et al[58] OS 
was 9% better after neoadjuvant therapy. This effect 
was seen 18 mo after surgery and lasted at least 10 
years. R0 resection was achieved 1.4 times more 
often after neoadjuvant treatment. Importantly, side 
effects of neoadjuvant therapy, such as postoperative 
morbidity or mortality, as well as prolonged hospital 
stay, were not increased significantly compared with 
surgery alone. Another interesting aspect was that no 
benefit of neoadjuvant therapy was seen in elderly 
patients. The subgroup of patients with EGJ cancer 
had the greatest benefit in OS. One of the unanswered 
questions is the age of patients recruited to the trial. 
Most trials excluded patients aged > 70 years. This 
issue is currently under investigation by a study in 
Germany. Another subgroup of patients of particular 
interest is those with signet ring cell carcinoma. They 
seem not to benefit from neoadjuvant treatment[59]. 
The response rate differs also according to pathological 
features. In DT tenors, a good pathological response 
was only observed in 14.5% of patients[60]. 
In Asian countries, neoadjuvant treatment is also 
beginning to play an important role. Currently several 
trials (JCOG 0210, JCOG 0501, JCOG 1002, and 
PRODIGY) are under way. In Italy, a GIRCG phase 
Ⅱ trial recruited patients with non-cardiac GC who 
underwent accurate pretreatment clinical staging 
with diagnostic laparoscopy and peritoneal washing, 
followed in all cases by standard D2 gastrectomy. 
This trial aims to answer whether preoperative or 
perioperative chemotherapy plays a role in advanced 
GC treatment (NCT01876927). 
Neoadjuvant CRT
As NC proved to be safe for preoperative treatment, 
the addition of radiotherapy to preoperative treatment 
has gained interest. The German POET trial compared 
NC vs CRT for locally advanced EGJ cancers[51]. In one 
arm, two courses of cisplatin, 5-FU and folic acid (PLF), 
followed by 3 wk of combined CRT (30 Gy in 3 wk with 
cisplatin/etoposide), and surgery were administered, 
vs 2.5 courses of PLF with surgery. This trial was 
closed early, and showed no significant difference in 
survival: 33.1 mo vs 21.1 mo in favor of CRT, but with 
higher mortality in the CRT arm: 10.2% vs 3.8% (P 
= 0.26). Results regarding 3-year survival showed an 
improvement from 28% to 48% in the CRT arm. 
In a study by Burmeister et al[61] on 75 patients, 
the addition of radiotherapy increased the rate of 
pathological complete remission (13% vs 0%, P = 
0.02), and reduced the rate of R1 resection (0% vs 
4%, P = 0.04). Analyzing 5-year OS and PFS, only a 
trend was observed in favor of CRT, without statistical 
significance (OS 45% vs 36%, P = 0.6).
In the CROSS trial from the Netherlands, patients 
with esophageal and EGJ cancers were assigned to 
CRT (carboplatin, paclitaxel and 41.4 Gy radiotherapy 
in 23 fractions) followed by surgery, vs surgery 
alone[52]. The surgery alone arm showed R0 resection 
in 69% of patients with a median survival time of 
24.2 mo, whereas in the neoadjuvant CRT arm, R0 
resection was achieved in 92% (P < 0.001), with 
complete pathological response rate in up to 29% 
of patients; however, it is noteworthy that in case 
of squamous cell carcinoma the complete response 
rate was better (49%) than for adenocarcinoma 
(23%). The median survival time was 49.4 mo (P 
= 0.003), and 5-year survival improved from 34% 
to 47%. Postoperative complications rate and in-
hospital mortality were similar in both arms (4%). 
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The neoadjuvant regimen also reduced locoregional 
recurrence rate (34% to 14%; P < 0.001), and the 
probability of PC (14% to 4%; P < 0.001). Distant 
metastases also showed a difference between both 
arms (35% vs 29%, P = 0.025). This treatment 
protocol is now recommended for neoadjuvant CRT 
in patients with EGJ adenocarcinoma in the US. The 
currently ongoing TOPGEAR trial is investigating CRT 
vs chemotherapy in EGJ and stomach cancers. In 
the chemotherapy arm, three courses of epirubicin, 
cisplatin and flurouracil (ECF) are given preoperatively, 
and in the CRT arm, two courses of ECF followed by 45 
Gy, or radiation with concurrent 5-FU. Patients in both 
arms receive three courses of ECF after surgery. 
A meta-analysis by Sjoquist et al[62] reviewed trials 
with localized gastroesophageal adenocarcinoma with 
preoperative CRT and chemotherapy alone. The hazard 
ratio for OS was 0.75.
Adjuvant chemotherapy
Analyzing data from different countries, the results 
of adjuvant chemotherapy after gastrectomy in 
western studies are less convincing than in Asian 
studies. In a Japanese study (ACTS-GC trial), oral 
fluoropyrimidine (S-1) was given after surgery for 1 
year, and results were compared with surgery alone. 
The 5-year OS was 70.1% vs 61.1%[53,54]. This trial 
was stopped earlier because of significantly better OS 
in the S-1 group. It needs to be underlined that the 
high rates of OS in both arms were due to excellent 
surgery, as D2 lymphadenectomy was confirmed in 
all cases. The problem in translating this trial into a 
Caucasian population is that Tegafur, present in S-1 
as a precursor of 5-FU, is transformed in the body by 
cytochrome P450 to 5-FU. The probable difficulties 
observed in Caucasians are due to polymorphism of 
CYP2A6 gene, and subsequent complications[63]. In the 
FLAGS trial, comparison of cisplatin + S-1 and cisplatin 
+ 5-FU for palliative therpy showed significantly better 
tolerance in patients with the addition of S-1[64]. 
In the CLASSIC trial, adjuvant chemotherapy 
with capecitabine and oxaliplatin after curative D2 
gastrectomy was compared with surgery alone[65]. 
This Asian trial showed significant improvements in 
3-year disease-free survival (DFS; 74% vs 59%, P 
< 0.0001), and OS (83% vs 78%, P = 0.0493). This 
trial was stopped earlier as the benefit of using this 
chemotherapy regimen was demonstrated. In the 
chemotherapy arm, oxaliplatin-induced peripheral 
neuropathy occurred in 56% of patients, but grade 
3/4 only occurred in 2% of cases. It seems that this 
regimen might be an alternative to the S-1 regimen. A 
meta-analysis on 17 trials of adjuvant chemotherapy 
after gastrectomy showed a small but significant 
benefit for 5-FU-based chemotherapy[66]. Adjuvant 
chemotherapy increased OS by 6%, and reduced the 
risk of death by 18%. A meta-analysis by Zhang et 
al[67] showed that four chemotherapy regimens may 
be effective: 5-FU + mitomycin C + adriamycin; 5-FU 
+ mitomycin C; tegafur; and mitomycin C. Other 
proposed regimens seem to be not so effective: 5-FU 
+ carmustine, 5-FU + methyl-semustine, 5-FU + 
cisplatin, 5-FU + anthracyclines, and 5-FU + mitomycin 
C + cytarabine. Another meta-analysis by the 
GASTRIC group (Global Advanced/Adjuvant Stomach 
Tumor Research International Collaboration) showed 
significant improvement in OS after 5-FU-based 
chemotherapy[66]. The same group in another meta-
analysis on advanced GC concluded that experimental 
arms of chemotherapy are responsible for modest 
improvement in OS and DFS (hazard ratio 0.88 and 
0.81). The median survival was below 1 year and none 
of the new regimens can be used as a standard[68].
Adjuvant CRT
The results of the INT-0116 trial by MacDonald et al[55] 
show that adjuvant CRT plays an important role in GC 
treatment. The problem of additional radiotherapy is 
the increased toxicity rate. Grade 3/4 hematological 
toxicity occurred in 54%, and gastrointestinal 
toxicity in 33% of patients. The toxic effect was also 
responsible for stopping the treatment in many cases. 
In patients with diffuse histology, the addition of 
radiotherapy did not confer any additional benefit. The 
biggest concern is about radiation of a large area of 
gastrointestinal mucosa. Current studies are focused on 
using 3D conformal and intensity-modulated radiation 
therapy (IMRT), and also new, safer radiotherapy 
techniques[69-71]. In a phase Ⅱ trial with 3D-CRT/IMRT, 
grade 3 or 4 nausea and vomiting (14.5%), decreased 
appetite (11.8%), leukopenia/neutropenia (9.1%) 
and fatigue (6.4%) were observed, and it proved to 
be a safe procedure[71]. We also need to mention that 
in the MacDonald et al[55] trial, an increased number 
(but not significant) of secondary malignancies after 
additional CRT were reported. The biggest challenge 
is to prove whether addition of radiotherapy to the 
regimen is better than chemotherapy alone. This issue 
was analyzed in the ARTIST trial[72]. No difference 
in 3-year DFS was observed between those two 
arms, but analyzing subgroups with lymph node 
metastases, 3-year DFS was improved in the CRT 
arm (77.5% vs 72.3%, P = 0.0365). This was also 
seen when adjusting for tumor stage. No difference in 
case of local or distal recurrence rate was observed. 
No OS results were reported in the 3-year analysis. 
The ARTIST-Ⅱ trial will investigate the influence of 
chemotherapy or CRT in patients with lymph-node 
positive GC. One particularly interesting aspect is that, 
in the INT-0116 trial, D2 resection was performed in 
only 10% of cases, whereas in most Asian studies, 
it is close to 100%. Indeed, local recurrences were 
observed in 29% of cases in the INT-0116 trial, vs 
2.8% in the Japanese ACTS-GC trial. It seems that the 
addition of radiotherapy confers a potential benefit to 
patients with a suboptimal surgical approach. This was 
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proved by a Dutch study, showing a reduction in local 
recurrences after CRT in patients with D1 resection, 
whereas this effect was not seen in the D2 resection 
group[73]. 
The problem of GEJ region radiotherapy is descri-
bed later. The main difficulty is that these patients 
are subgroups in esophageal cancer and GC trials. 
Some of these problems were mentioned above, for 
example, in a neoadjuvant setting as in the CROSS 
trial[52]. After GEJ surgery, additional CRT is based on 
the INT-0116 trail (approximately 20% of patients in 
this trial had a GEJ location)[55]. In the current AJCC 
staging, GEJ tumors are staged as esophageal and not 
as gastric. The only trial exclusively for GEJ tumors 
was done in Germany, analyzing neoadjuvant CRT vs 
chemotherapy alone[51]. There was a higher rate of 
complete pathological response (15.6% vs 2%), and a 
trend towards improved 3-year survival (47% vs 28%, 
P = 0.07) in favor of neoadjuvant CRT[51].
The German trial also tried to identify those 
patients who would benefit from neoadjuvant therapy 
using positron emission tomography/computed 
tomography[74]. The MUNICON study tried to predict 
response after 2 wk of NC in GEJ cancer. Non-responders 
to chemotherapy underwent surgery, sparing them 
from unnecessary toxicity, as well as undergoing 
surgery earlier. It should also be noted that most GEJ 
tumors are fluorodeoxyglucose (FDG) sensitive, but in 
30% they do not take up FDG[75]. The solution might 
be to use radioisotopes such as fluorothymidine for 
GC[76]. The most important studies from multimodal GC 
treatment are presented in Table 1.
Targeted therapies
The new drugs that may be used in targeted thera-
pies probably play an increasing role in modern 
treatment of GC. Epidermal growth factor receptor 
(EGFR) is overexpressed in most GC. The trials that 
used anti-EGFR antibody cetuximab (EXPAND trial), 
and panitumumab (REAL3 trial) failed to improve 
survival in GC patients[77,78]. In REAL3, panitumumab 
was shown to actually worsen survival of treated 
patients[78]. Another antibody tested in an adjuvant 
setting in GC is bevacizumab against vascular 
endothelial growth factor A. In the AVAGAST trial, 
this antibody did not improve OS when added to 
standard chemotherapy[79]. Overexpression of human 
epidermal growth factor receptor-2 (HER-2/neu) is 
present in > 20% of patients with GC. An antibody 
against this receptor - trastuzumab - showed signi-
ficant improvement in OS in metastatic gastric and 
GEJ cancers in the ToGA trial[80]. The oral antibody 
lapatinib is currently being investigated for HER-2-
positive GC in the LOGIC trial. Currently, we await 
the results of ongoing trials using molecular-targeted 
drugs in GC: LOGIC (lapatinib), TYTAN (lapatinib), 
RAINBOW (ramucirumab), GRANITE-1 and GRANITE-2 
(everolimus). We also need to mention that currently 
many drugs are being tested in phase Ⅰ and Ⅱ trials, 
such as the recently finished phase Ⅱ trial of apatinib, 
with promising results[81,82]. From the molecular point 
of view, the greatest interest lies in drugs that will 
7962 July 14, 2015|Volume 21|Issue 26|WJG|www.wjgnet.com
Table 1  Main trials regarding adjuvant and neoadjuvant therapy for gastric cancer reported in literature
Trial name Therapy Treatment arms Tumor position OS P  vaule PFS/DFS P  vaule
Neoadjuvant CT
MAGIC[48] CT Perioperative GC + EGJ 0.009 < 0.001
Res. vs mult
FNLCC/FFCD 9703[49] CT Perioperative GC + EGJ 0.021    0.003
Res. vs mult
EORTC 40954[50] CT Preoperative GC + EGJ 0.466 NS    0.200
Res. vs mult NS
Neoadjuvant CRT
POET[51] CRT Preoperative EGJ (I, Ⅱ, Ⅲ) 0.07    0.060
CRT vs mult CT NS (3 yr) NS (3 yr)
CROSS[52] CRT Preoperative Esophagus + EGJ I, 
Ⅱ, Ⅲ
0.003 < 0.001
 Res. vs mult CRT
Adjuvant CT
ACTS-GC[53,54] CT Postoperative Not given 0.002 < 0.001
Res. vs mult
CLASSIC[65] CT Postoperative GC + EGJ 0.049   < 0.0001
Res. vs mult (3 yr) (3 yr)
Adjuvant CRT
INT 0116[55] CRT Postoperative GC + EGJ 0.005 < 0.001
Res. vs mult
ARTIST[72] CRT Postoperative GC Not given      0.0824
Res. vs mult NS (3 yr)
CT: Chemotherapy; CRT: Chemoradiotherapy; GC: Gastric; EGJ: Esophageal gastric junction; OS: Overall survival; PFS/DFS: Progression-free survival/
disease-free survival; Mult: Multimodal treatment; Res: Surgical resection alone.
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be effective against VEGR2, c-MET, FGFR1, 2, HER2, 
HER3, and members of the PI3K/AKT/mTOR pathway. 
Hyperthermic intraperitoneal chemotherapy
In advanced cases PC of gastric origin is a condition 
with poor prognosis, with a mean survival range of 
2.2-8.8 mo and no 5-year survival probability[30]. 
The peritoneal surface is a preferential site of GC 
dissemination. The current lack of efficient systemic 
therapy has led many clinicians to combat this 
localized disease by intraperitoneal administration of 
cytotoxic agents (intraperitoneal chemotherapy; IPEC). 
Other possible delivery options have been described, 
like perioperative normothermic intraperitoneal 
chemotherapy (NIPEC), hyperthermic intraperitoneal 
chemotherapy (HIPEC), early postoperative intra-
peritoneal chemotherapy (EPIC), and delayed 
postoperative intraperitoneal chemotherapy (DIPEC)[83]. 
As Spratt in 1980 proposed HIPEC with additional 
cytoreductive surgery, this new therapeutic option 
began to play an important role in advanced GC[84]. The 
advantage of HIPEC in comparison with other ways of 
delivering IPEC is the combined effect of cytostatic drug 
and heat, which results in a greater cytotoxic effect on 
the cancer cells[30]. Neoadjuvant as well as adjuvant 
treatment showed a potential benefit in decreasing 
rates of PC[85]. Initial IPEC studies showed that 
patients receiving chemotherapy intraperitoneally with 
mitomycin C, but also cisplatin and 5-FU had better OS 
after curative resection of locally advanced GC[86]. After 
the first report by Fujimoto et al[87] regarding HIPEC 
in patients with secondary PC, others have used that 
technique for PC of GC origin. In one of the biggest 
studies on 107 patients treated with HIPEC, Yonemura 
et al[88] showed that patients who underwent complete 
resection had better 5-year survival than those with 
residual disease (13% vs 2%). The completeness of 
resection was an independent prognostic factor[89,90]. A 
French multi-institutional study on 159 patients showed 
that radical resection and HIPEC were associated with 
a 5-year survival rate of 23%[83]. However, it should 
be emphasized that only a small proportion of patients 
who underwent complete macroscopic cytoreduction 
(R0 or R1) had a chance of survival in that study.
Another issue is PC after radical gastrectomy. The 
peritoneal surface is the most common site of GC 
recurrence after surgery. After curative resection, 
PC may occur in 20%-50% of cases, and rises up to 
80% in cases with positive peritoneal cytology[91,92]. 
The biggest problem is that adjuvant intravenous 
chemotherapy or radiotherapy does not improve 
survival in patients at high risk of PC. Only IPEC 
may prevent the development of PC, and addition of 
hyperthermia synergistically with some drugs increases 
the depth of penetration into the tissue[30]. 
At least two meta-analyses have studied IPEC. In 
the first by Xu et al[93] of 11 randomized clinical trials, 
seven compared surgery + HIPEC vs surgery alone. 
IPEC was superior after curative surgery vs surgery 
alone, and combination of HIPEC and activated carbon 
particles was significantly better than other drug 
combinations. The second meta-analysis, by Yen et 
al[94], reviewed all clinical trials of IPEC. Among 13 
trials, four of them investigated the efficacy of HIPEC, 
five NIPEC, two EPIC, two combined HIPEC and EPIC, 
and finally, two trials reported the combined effects 
of DIPEC. All data form 1648 patients showed a 
significant difference in survival of patients treated with 
HIPEC, or HIPEC together with EPIC. A trend toward 
survival improvement was observed with NIPEC. No 
benefit was seen using EPIC or DIPEC. In our opinion, 
the addition of HIPEC may provide a survival benefit 
in patients at high risk of PC after gastrectomy, such 
as patients with diffuse-mixed type, serosal invasion, 
or positive peritoneal cytology. HIPEC is an effective 
treatment in patients with free cancer cells and cancer 
microfoci, but becomes less effective as the tumor 
size increases, and the disease is disseminated[30]. 
A new trial is ongoing to prove the effectiveness of 
HIPEC during curative gastrectomy in case of positive 
peritoneal cytology (GASTRICHIP trial). This new 
perspective can probably assist wider usage of HIPEC 
to prevent further PC. 
Metastatic GC
GC is often diagnosed as an advanced disease, 
especially in western countries where no screening 
for early diagnosis is used. The surgical resection 
of all pathological tissues is essential for curative 
treatment, and in most cases of advanced disease, it 
is not possible. Palliative chemotherapy for stage Ⅳ 
GC is a treatment of choice. Because of improvement 
of modern chemotherapy, better response, and 
usage of surgical techniques, survival of stage Ⅳ GC 
has improved during recent decades. The biggest 
question is who will benefit from more aggressive 
treatment, especially keeping in mind that extended 
survival is important, as well as patients’ quality of 
life (QoL)[95]. The role of surgery even in primarily 
incurable disease has increased because some patients 
who respond well to chemotherapy might be restaged 
and eventually undergo surgery. Unfortunately, the 
outcomes measured in most studies are limited to 
survival. Surgical palliation should be defined as a 
treatment that relieves symptoms or improves QoL[96]. 
Surgical resection that does not remove all pathological 
masses should be named as noncurative rather than 
palliative. In the SEER database of 23830 patients 
with stage Ⅳ disease, surgery was offered to 45.7% 
of patients. Overall, the median survival was only 4 
mo. The surgical approach is associated with some 
survival advantages compared with other palliative 
treatments. In the study by Li et al[97] on a group of 
253 synchronous GC metastases, 5-year survival 
was 6.5% for patients with resection vs 0% without 
surgery. Multivariate analysis proved that patients 
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with liver metastases, peritoneal dissemination, and 
those without resection deteriorated. The survival 
difference between groups with or without resection 
was only seen with those who had single site peritoneal 
dissemination. The Cochrane review found that 
chemotherapy improved survival over best supportive 
care in patients with incurable GC[98]. The authors also 
stated an advantage for combination chemotherapy 
over single agent approaches. The improvement in 
tumor response after multimodal treatment again 
raises a question about the surgical approach. In a 
Japanese study of 28 patients who responded well to 
S-1-based chemotherapy, there was a 93% rate of 
R0 resection. A complete response was seen in four 
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Figure 5  Proposal of a tailored multimodal approach in resectable non-cardiac gastric cancer. JGCA: Japanese Gastric Cancer Association; NAC: Neoadjuvant 
chemotherapy; HIPEC: Hyperthermic intraperitoneal chemotherapy.
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patients, and the median survival was 29 mo, with 
34% 5-year survival[99]. In the French FREGAT study, 
palliative gastrectomy was performed because of solid 
organ metastases (5.6%), localized PC (4.6%), diffuse 
PC (2.3%) or incomplete tumor resection (12.8%)[100]. 
Median survival of patients with resection was better 
than in the non-resection group (11.9 mo vs 8.5 mo, 
P < 0.001). Multivariate analysis proved that factors 
associated with survival were: ASA score Ⅱ-Ⅳ, localized 
PC, diffuse PC, and signet ring histology. Patients with 
ASA Ⅰ/Ⅱ and incomplete resection without metastasis 
or PC, one-site solid organ metastasis without PC, or 
localized PC without signet ring cell histology, showed 
the highest benefit from surgery. This subgroup of 
patients had median survival from 12 to 18.3 mo. 
Analyzing surgical treatment in the case of distant 
metastases, we must also mention treatment of liver 
metastases from GC. No trials have been performed in 
this field, and a recent review by Grimes et al[101] was 
based on 17 retrospective studies. The solitary disease 
patients had better OS than those with metachronous 
disease, and patients with metachronous disease had 
better prognosis than those with synchronous disease. 
Hepatectomy in these patients is a safe procedure with 
about 2% perioperative mortality, and morbidity from 
17% to 60%. The authors state that metachronous 
metastatic disease limited only to the liver, with the 
possibility of surgical resection, should be consider in a 
clinical trial. 
In the latest GIRCG study on synchronous hepatic 
metastases in cases of GC, it was clear that clinical 
criteria could be used to select candidates for curative 
surgery. The surgical approach has an impact on 
survival especially when adjuvant chemotherapy is 
added[102].
Multivisceral resection of advanced forms
The role of multivisceral resection, in the setting 
of locally advanced GC, has been evaluated in 
several studies. Most of them reported a higher 
risk for perioperative morbidity and mortality, with 
limited objective benefit in terms of survival, but a 
potential advantage of extended resection for some 
subgroups[103]. In a recent GIRCG study, 206 patients 
with a clinical T4b carcinoma were evaluated[104].
One hundred and twelve patients underwent 
combined resection of the adjacent organs for 
clinical T4b stage disease. Postoperative mortality 
and complication rates were acceptable, and overall 
5-year survival rate was 27.2%. The completeness of 
resection and lymph node invasion were independent 
prognostic parameters at multivariate analysis. At 
present, even if a chance of cure with an extended 
surgical approach could be obtained in subgroups of 
patients with invasion of adjacent organs, a multimodal 
approach should include neoadjuvant treatment, 
followed by extended surgery in responders. The 
addition of HIPEC should be considered.
CONCLUSION
Results of treatment in specialized western centers 
are good in early stage (Ⅰ/Ⅱ) GC, but are still unsatis-
factory in more advanced stages (ⅢB and higher), 
when compared with eastern studies. Treatment options 
have changed in recent years from a standard to a 
tailored approach. Different individualized procedures 
can range from endoscopic resection, D2 with open or 
minimally invasive approach, to neoadjuvant therapy 
followed by extended surgery (Figure 5). In more 
advanced stages, a combined approach with the 
inclusion of HIPEC may represent a new frontier for 
multimodal treatment of resectable GC. It should be 
also emphasized that tailored treatment of GC involves 
appropriate pretreatment clinical staging of the disease. 
Clinicians should expect to face, in the future, fewer GC 
cases, but with higher biological aggressiveness, due 
to the relative increase of proximal and DT tumors. The 
high propensity of DT to lymph node metastasis and 
peritoneal dissemination makes multimodal treatment, 
in particular including NC and HIPEC, a modern and 
necessary approach to this still fatal disease.
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